Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Stage III Melanoma: early-phase trial registry
A small indexed set (6 trials) with no open enrollment listed right now.
Corpus placement: #2,866 of 28,707 conditions by registered trial count.
6 US clinical trials · none currently recruiting · #2,866 of 28,707 conditions by registered trial count
Stage III Melanoma: 6 US clinical trials tracked, none currently recruiting.
Stage III Melanoma is the subject of 6 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 4 of these trials.
Enrollment posture brief
Registry condition stage-iii-melanoma
OPEN 0 | RECR 0% | LATE 0 | EARLY 5 | RANK #2866 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Stage III Melanoma has no open enrollment in this registry pull (6 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Stage III Melanoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Stage III Melanoma is recruiting below its size-band peers.
0 of 6 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Stage III Melanoma research.
National Cancer Institute (NCI) accounts for 4 of 6 trials (66.7%). 3 distinct sponsors appear on at least one study for this condition label.
-
Most Stage III Melanoma trials plan to enrol fewer than 100 people.
Median target enrolment is 69 among the 6 trials that report a genuine target (sentinel values excluded). 6 of those (100%) plan for fewer than 100 participants.
-
Stage III Melanoma research is mostly interventional.
5 interventional and 1 observational studies make up this index (83.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Indexed trials (enrollment closed)
6 total, page 1 of 1
Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy
Emory University
NCT03719131
Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
NCT00119249
Leveraging ctDNA Analysis to Improve Early Detection of Cancer Recurrence in the High-Risk Melanoma Setting
Case Comprehensive Cancer Center
NCT05079113
Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma
National Cancer Institute (NCI)
NCT00349206
Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers
National Cancer Institute (NCI)
NCT00074308
Decitabine in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
NCT00030615
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Stage III Melanoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Stage III Melanoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Stage III Melanoma page
6 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Stage III Melanoma trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- National Cancer Institute (NCI) sponsors the most Stage III Melanoma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Stage III Melanoma condition card totals 6 registered trials; most-linked intervention laboratory biomarker analysis; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.